Health Journal Online

Category: Diseases & Conditions

  • 40% of American Children Ages 6–19 Are Now Nearsighted — Here’s the Evidence-Based Plan to Slow Pediatric Myopia

    40% of American Children Ages 6–19 Are Now Nearsighted — Here’s the Evidence-Based Plan to Slow Pediatric Myopia

    Forty percent of American children between the ages of 6 and 19 are currently nearsighted, according to the American Academy of Ophthalmology. In Asia, the rate is nearly double. Worldwide, researchers project that if current trajectories continue, 50% of the global population will be myopic by 2050 — a figure that was once considered alarmist and is now regarded as a conservative estimate by the ophthalmology community.

    This is not simply an inconvenience that corrective lenses can fix. Myopia, when it progresses to its most severe form, dramatically elevates the risk of potentially blinding conditions: retinal detachment, glaucoma, early cataracts, and myopic maculopathy. According to the AAO, children who develop myopia early and progress to high myopia face a 50% greater risk of glaucoma, are 17% more likely to need cataract surgery, and carry a 6-fold greater risk of retinal detachment and retinal tears. The disease burden that will materialize in adult life as today’s myopic children age represents one of the most significant preventable vision crises in history.

    “Kids who develop myopia early in life and progress to high myopia face an uncertain future,” the AAO stated in its myopia epidemic initiative. “The time to intervene is in childhood.”

    Why Myopia Is Rising — The Screen Time and Outdoor Time Evidence

    The primary drivers of the pediatric myopia epidemic are now well-characterized in the scientific literature, even if the precise mechanisms are still being refined. Two behavioral factors dominate: increased time spent on close-range visual tasks (near work, including screens), and reduced time spent outdoors.

    Near work and prolonged close focusing. When the eye focuses on objects at close range for extended periods, it may receive signals that promote axial elongation — the physical lengthening of the eyeball from front to back that defines myopia. The visual cortex signals involved are not yet fully characterized, but the epidemiological pattern is consistent across multiple studies: populations with higher near-work exposure have higher myopia rates.

    The COVID acceleration. The pandemic provided an inadvertent natural experiment. As Contemporary Pediatrics documented in its April 2026 comprehensive review, home confinement and distance learning drove children’s average daily screen time from approximately 2.1 hours to 5.6 hours per day. The result was a measurable, documented surge in myopia onset and progression, particularly in children ages 6 to 8 — the developmental window during which the eye’s growth rate is highest, and myopia risk is most acute.

    The outdoor time protective effect. This is the finding with the strongest intervention potential. Time spent outdoors — not necessarily time spent looking at distant objects — appears to protect against myopia onset and slow its progression in children who already have it. The AAO attributes this primarily to bright outdoor light (typically 10,000 to 100,000 lux) triggering the release of dopamine in the retina, which signals the eye to slow its axial growth. Indoor lighting typically delivers only 300–500 lux — insufficient to trigger the same protective signal.

    As the AAO describes: “A study of a school-based program in Taiwan that encouraged kids to spend 11 hours a week outdoors showed that sunlight can decrease myopia progression.” That 11 hours per week — roughly 80 minutes per day — is the threshold that research identifies as protective. Most American children get significantly less.

    Pediatric Myopia Epidemic — Key Data Detail
    U.S. children (ages 6–19) who are myopic ~40% (American Academy of Ophthalmology)
    Global myopia projection by 2050 ~50% of world population
    Asian rates (children and young adults) 80–90% in East/Southeast Asia
    U.S. myopia increase in past 50 years Nearly doubled (from ~21% to ~41.6%)
    COVID-era screen time shift 2.1 hrs/day → 5.6 hrs/day (significant myopia acceleration)
    Age group most at risk for rapid progression 6–8 years during pandemic school closures
    High myopia glaucoma risk increase 50% greater
    High myopia cataracts risk increase 17% more likely to need cataract surgery
    High myopia retinal detachment risk 6x greater
    Protective outdoor time threshold ~11 hours/week (80+ min/day)
    Outdoor light vs. indoor light Outdoor: 10,000–100,000 lux; indoor: 300–500 lux
    Mechanism of outdoor protection Bright light triggers retinal dopamine release, slowing axial growth
    Treatment options beyond glasses Low-dose atropine eyedrops; orthokeratology contact lenses; defocus contact lenses
    Age to begin eye exams First exam by age 1 (AAO recommendation); age 3 for full assessment

    Evidence-Based Interventions — What Actually Slows Myopia in Children

    The encouraging news is that myopia progression is not inevitable in the way the epidemic trajectory might suggest. Specific interventions have documented efficacy for slowing or preventing progression:

    Outdoor time — the most accessible intervention. Based on the Taiwan school program and multiple subsequent studies, increasing children’s daily outdoor time to 80+ minutes significantly reduces both myopia onset risk and the rate of progression in children who already have it. This does not require structured eye exercises or specific activities — simply being outside in bright natural light appears sufficient. Pediatricians can prescribe outdoor time just as specifically as they prescribe medication.

    Low-dose atropine eyedrops. Atropine at 0.01% concentration, applied once daily at bedtime, has been shown in multiple randomized trials to slow myopia progression by approximately 50–60% compared to controls, with minimal side effects. The mechanism is not fully characterized but appears to involve direct effects on retinal signaling rather than the pupil dilation seen with higher atropine doses. Low-dose atropine is increasingly used in pediatric ophthalmology practices for children with documented myopia progression, typically in children between ages 7 and 14.

    Orthokeratology (ortho-k) and specialty contact lenses. Rigid gas-permeable contact lenses worn overnight (orthokeratology) reshape the cornea during sleep and simultaneously reduce the peripheral defocus pattern thought to drive axial growth. Soft multifocal contact lenses and “defocus incorporated multiple segment” (DIMS) lenses achieve similar myopia control effects through optical means. These options are typically discussed with a pediatric ophthalmologist or optometrist with myopia management expertise.

    Screen time management — necessary but not sufficient alone. Reducing screen time matters, but the primary driver of the protective benefit appears to be adding outdoor time rather than simply reducing screen time. As Clearview Eyes’ 2026 guidelines review noted: “After the restrictions were lifted and screen time was reduced, the trend of myopia worsening or slowing down happened” — but the most effective intervention is the replacement of indoor time with outdoor time, not merely passive reduction of device use.

    What Parents and Pediatricians Should Do Starting Now

    For parents: Prioritize outdoor play as a health intervention, not merely recreation. Aim for 80+ minutes of daily outdoor time for children from early childhood. Use the AAO and AAPOS screen time guidelines as a starting point (no more than 1 hour per day for ages 2–5, and more flexible but structured limits with outdoor balance for older children). Ensure annual eye exams beginning at age 3, and ask specifically about myopia management options if your child is already myopic and showing progression.

    For pediatricians: The AAO and American Association for Pediatric Ophthalmology and Strabismus (AAPOS) joint clinical statement recommends routine vision screening at well-child visits. Asking about daily outdoor time at every well-child visit is a low-cost, high-yield intervention. Children with myopia onset before age 10, documented rapid progression, or parental myopia in both parents warrant early referral to a pediatric ophthalmologist for myopia management discussion.

    For schools: The Taiwan evidence suggests that school-based policies increasing outdoor recess and limiting prolonged continuous close work time can measurably reduce population-level myopia rates. Schools with longer, more frequent outdoor breaks show lower myopia prevalence in controlled comparisons.

    Frequently Asked Questions

    How common is myopia in American children?

    The American Academy of Ophthalmology estimates approximately 40% of American children ages 6–19 are currently nearsighted. This nearly doubles the rate from 50 years ago. In East and Southeast Asia, rates reach 80–90% among children and young adults.

    Why is myopia becoming an epidemic?

    The primary drivers are reduced outdoor time (children now spend significantly less time outside in natural light than prior generations) and increased near-work exposure from screens and close-range learning. The COVID pandemic accelerated myopia onset and progression by dramatically increasing screen time and reducing outdoor activity.

    Is high myopia different from regular nearsightedness?

    Yes. High myopia (refractive error greater than -6 diopters) is associated with significantly elevated risks of retinal detachment (6x higher), glaucoma (50% higher), cataracts (requiring surgery 17% more often), and myopic maculopathy — a leading cause of blindness in myopic individuals. This is why slowing myopia progression in childhood matters so much.

    What is the most effective intervention for preventing myopia?

    Increasing outdoor time to approximately 80 minutes or more per day is the most accessible and evidence-supported intervention for reducing myopia onset and slowing progression. Bright outdoor light (10,000–100,000 lux, far above indoor lighting) triggers retinal dopamine release that slows the axial eye growth that drives myopia.

    What treatments are available if my child already has myopia?

    Beyond corrective glasses or contact lenses, evidence-based myopia management options include: low-dose atropine 0.01% eyedrops (approximately 50–60% slowing of progression), orthokeratology (overnight rigid contact lenses that slow axial growth), and specialized soft multifocal contact lenses. These are typically managed by a pediatric ophthalmologist with myopia management expertise.

    Source link

  • Philadelphia Declares a Heat Health Emergency — Cooling Centers Open, Field Teams Dispatched, Heatline Active

    Philadelphia Declares a Heat Health Emergency — Cooling Centers Open, Field Teams Dispatched, Heatline Active

    Philadelphia declared a Heat Health Emergency on June 19, 2026, as the Juneteenth heat wave — which has placed approximately 80 million Americans under some form of heat advisory — brought heat index values forecast to reach 103°F and potentially exceed 100°F in the city.

    The declaration — issued by Philadelphia Health Commissioner Dr. Palak Raval-Nelson — activates a comprehensive set of city services designed specifically to reach those most at risk from heat illness and death: elderly residents living alone without air conditioning, people experiencing homelessness, outdoor workers, and residents with medical conditions that impair heat tolerance. “The Health Department declares a Heat Health Emergency when the temperature gets high enough that vulnerable people — especially our elderly neighbors and family members — are at an increased risk of getting sick or dying from the heat,” Commissioner Raval-Nelson said.

    This is not Philadelphia’s first heat health emergency of the summer. The Keystone Newsroom’s June 2026 coverage documented that Philadelphia had already come through two prior heat events in early June — the city’s first and second heat waves of 2026 — with temperatures reaching 97–98°F on consecutive days. The June 19 Juneteenth declaration represents the third heat emergency activation of the season.

    What a Philadelphia Heat Health Emergency Actually Activates

    According to the City of Philadelphia’s official Heat Health Emergency services page, a declaration triggers a coordinated set of emergency programs that go significantly beyond issuing a public advisory. The full activation includes:

    The Heatline — 215-765-9040. The Philadelphia Corporation for Aging’s (PCA) Heatline opens for calls during extended hours (8:30 a.m. to 8:30 p.m. during the emergency). City Health Department nurses answer calls directly, available to discuss medical concerns related to the heat, identify whether callers are in danger, and help connect residents with appropriate services. This is not a call center with scripted responses — it is a nurse-staffed clinical support line.

    Cooling centers with extended hours. As confirmed by the Philadelphia Inquirer’s coverage of the June 11 emergency and CBS Philadelphia, dozens of cooling centers open at community centers, libraries, religious centers, and parks across the city — with extended hours specifically during Heat Health Emergencies. Residents can find cooling center locations and hours at phila.gov or by calling 311. Parks and Recreation Older Adult Centers are open specifically for elderly residents.

    Home visits by special field teams. This is perhaps the most operationally significant activation in the declaration. As the City of Philadelphia’s public health documentation confirms, home visits by specialized field teams go to elderly residents and others identified in city health databases as being at elevated risk — people who may not access general public advisories, who may not know to call the Heatline, and who may be in danger before their distress is visible to neighbors or family. This proactive outreach distinguishes Philadelphia’s response from systems that rely entirely on self-reporting.

    Homeless outreach mobilization. The city mobilizes Homeless Services personnel and street outreach teams to offer shelter and services to people sleeping outside. As documented by both Philadelphia Patch and the Philadelphia Inquirer, street teams patrol the city offering shelter and services to anyone found outside in dangerous conditions. A 24/7 outreach hotline is available at 215-232-1984 for anyone who spots a person outside in need of help.

    Utility shutoff suspension. Residential utility shutoffs for nonpayment are suspended during Heat Health Emergencies, ensuring that residents who are behind on bills are not left without power for air conditioning during the most dangerous heat period.

    Pool access expansion. Philadelphia Parks & Recreation opens more than 60 outdoor pools on a rolling basis during Heat Health Emergencies, with free swim during open hours.

    Philadelphia Heat Health Emergency — Activated Services Detail
    Declaration authority Health Commissioner Dr. Palak Raval-Nelson
    Heatline 215-765-9040 (8:30 a.m. – 8:30 p.m. during emergency)
    Cooling centers Dozens of locations; community centers, libraries, religious centers, parks; call 311
    Home visit teams Special field teams dispatched to high-risk elderly and other identified residents
    Homeless outreach Mobilized Homeless Services personnel and street outreach teams
    24/7 homeless/outreach hotline 215-232-1984
    Outdoor pools 60+ opened on rolling basis; free swim during emergency
    Utility shutoffs Suspended during emergency (no shutoffs for nonpayment)
    Older Adult Centers Open with AC during emergency hours
    Heat index forecast 103°F + possible triple digits
    2026 context Third heat wave for Philadelphia; June 11–12 and prior June events also declared emergencies

    Philadelphia’s Specific Heat Vulnerabilities

    Philadelphia is one of the most heat-vulnerable large cities on the U.S. East Coast for reasons that go beyond temperature — they are structural.

    The urban heat island effect is severe. Philadelphia’s dense urban fabric — asphalt, concrete, limited tree canopy in many low-income neighborhoods — means that the city retains significantly more heat than surrounding suburban and rural areas. During a heat wave, urban core temperatures regularly exceed surrounding area temperatures by 5–10°F. Low-income and predominantly Black and Hispanic neighborhoods consistently show less tree coverage and higher surface temperatures than wealthier neighborhoods — a documented environmental justice disparity that concentrates the health burden of heat on the populations least resourced to address it.

    Air conditioning access gaps remain. While the majority of Philadelphia households have air conditioning, significant gaps remain among elderly residents on fixed incomes who avoid running AC to limit electricity bills, low-income renters whose landlords are not required to provide adequate AC, and residents in older housing stock where window units are not feasible.

    Older adults living alone. Philadelphia has a substantial elderly population, and a significant proportion of seniors live alone. During the 1995 Chicago heat wave — which killed 739 people in six days and remains the defining case study for heat mortality in a major U.S. city — living alone was one of the single strongest predictors of death, particularly when combined with no air conditioning and social isolation. Philadelphia’s home visit program exists precisely to address this known risk pattern.

    Anyone in Philadelphia who is concerned about themselves or a family member during the heat emergency should call 311 to find the nearest cooling center, call the PCA Heatline at 215-765-9040 to speak with a nurse, or call the 24/7 outreach line at 215-232-1984 for immediate street outreach assistance.

    Frequently Asked Questions

    What does Philadelphia’s Heat Health Emergency declaration activate?

    The declaration activates: the PCA Heatline at 215-765-9040 (nurse-staffed); cooling centers with extended hours at dozens of locations; home visits by specialized field teams to high-risk residents; mobilization of Homeless Services personnel and street outreach teams; free pool access; and suspension of residential utility shutoffs for nonpayment.

    Where can I find a cooling center in Philadelphia?

    Call 311 or visit phila.gov to find the nearest cooling center. During the Heat Health Emergency, dozens of locations are open with extended hours, including community centers, libraries, religious centers, parks, and Older Adult Centers.

    How do I get help for someone who appears to be in heat distress outdoors in Philadelphia?

    Call the 24/7 outreach line at 215-232-1984 to request immediate assistance for anyone you find outside who may be in heat distress. For a life-threatening emergency, call 911.

    What is the Heatline, and when is it available?

    The Philadelphia Corporation for Aging’s Heatline (215-765-9040) is staffed by City Health Department nurses during Heat Health Emergencies. Hours are 8:30 a.m. to 8:30 p.m. Nurses can answer medical questions about heat-related health concerns and help connect callers with services.

    Is there free swimming available during the emergency? Yes. Philadelphia Parks & Recreation opens its 60+ outdoor pools on a rolling basis during Heat Health Emergencies, with free swim during open hours. Check phila.gov for current open pool locations.

    Source link

  • Billion in Rural Health Funding Won’t Reopen Martin County’s Closed Hospital — Here’s What the Fine Print Actually Says

    $50 Billion in Rural Health Funding Won’t Reopen Martin County’s Closed Hospital — Here’s What the Fine Print Actually Says

    Stanley Sears was 50 years old when he had a heart attack in Martin County, North Carolina. Emergency crews from a neighboring town worked on him for half an hour, but couldn’t revive him for the long drive to the closest hospital. Martin County’s only hospital had closed a year before his death.

    His sister, Debra Pierce, still wonders. “The sad thing is we’ll never know if he could have been saved that night or not, because we don’t have a higher level of care in this county,” she told KFF Health News reporter Sarah Jane Tribble.

    In the political moment following the passage of the One Big Beautiful Bill Act, the story of Martin County is being told differently by different people. Republicans point to the $50 billion Rural Health Transformation Program included in the bill as evidence that rural communities will be helped. Martin County Manager Drew Batts, who has walked through the shuttered corridors of Martin General Hospital with federal and state lawmakers, has a simpler assessment: “The $50 billion is not something that is specifically going to help our situation. It’s not going to help us get this place reopened.”

    He is correct. And the reasons why are an object lesson in the gap between what a federal health fund promises and what it can actually deliver.

    What the $50 Billion Rural Health Fund Is — and What It Isn’t

    According to KFF’s comprehensive analysis of the fund, the Rural Health Transformation Program was added to the One Big Beautiful Bill Act in response to concerns from lawmakers representing rural states about the bill’s massive Medicaid cuts. The fund provides $10 billion per year over five years (fiscal years 2026–2030), for a total of $50 billion. CMS has broad discretion over distribution and — critically — those distribution decisions are not subject to administrative or judicial review.

    The fund’s structural design creates several limitations that directly affect communities like Martin County:

    Limitation 1: The fund goes to existing organizations, not to closed facilities. North Carolina distributes its $213 million first-year allocation among existing health and social service organizations. As KFF Health News reported, federal regulations set limits on how much can be spent on construction and building renovations. Martin General Hospital isn’t open — so it isn’t an existing organization that can receive funds.

    Limitation 2: The hub-and-spoke distribution model concentrates money in larger systems. North Carolina’s plan creates a hub-and-spoke model that allots money to six large regional leads, including nonprofits such as ECU Health’s affiliate Access East. Those hubs then distribute to local entities. ECU Health’s affiliate did win a portion of North Carolina’s first-year payout — but the federal money cannot be used to reopen Martin General, according to ECU Health’s Chief Operating Officer Brian Floyd.

    Limitation 3: The fund is temporary; the Medicaid cuts are not. KFF analysis shows the $50 billion could offset approximately 37% of the estimated cuts to federal Medicaid spending in rural areas ($137 billion over ten years). But while the rural health fund is limited to five years, nearly two-thirds of the ten-year reductions in federal Medicaid spending occur after fiscal year 2030 — meaning the fund’s support runs out before most of the damage it’s supposed to offset materializes.

    Limitation 4: The math doesn’t work for the most rural communities. KFF analysis shows that Connecticut (with 3 rural hospitals by one definition) could receive the same amount as Kansas (with 90 rural hospitals) if both states are approved for funding. The allocation formula gives equal weight to states regardless of rural hospital density, diluting the fund’s impact in states most desperately in need.

    $50 Billion Rural Health Fund — Key Facts Detail
    Total fund size $50 billion ($10B/year for FY 2026–2030)
    Authorizing legislation One Big Beautiful Bill Act
    CMS discretion over distribution Broad; not subject to administrative or judicial review
    NC first-year allocation $213 million
    Distribution model in NC Hub-and-spoke; six large regional lead organizations
    Can NC funds reopen Martin General? No — federal rules limit construction; hospital must be operational
    Fund’s offset of rural Medicaid cuts ~37% of estimated $137B in rural Medicaid cuts over 10 years
    Timing mismatch Fund runs FY 2026–2030; 64% of Medicaid cuts come after FY 2030
    Martin County’s situation 22,000 residents; no hospital since 2023; no paramedics on ambulances
    Distance to nearest ER 20+ miles
    ECU Health projected Medicaid cut impact $1 billion over 10 years (CEO testimony)

    What Martin County Actually Needs — and What It Would Take

    ECU Health signed a letter of intent to reopen Martin General as a rural emergency hospital (REH) — a federal designation that allows smaller facilities to operate with 24-hour emergency services and outpatient care but without inpatient beds. Under that plan, Martin County would pay to refurbish the hospital, and the North Carolina General Assembly would need to provide ECU Health with $210 million — of which $150 million would fund construction of a new inpatient tower at ECU’s Beaufort Hospital.

    That legislative appropriation has not materialized. And even if it did, Representative Don Davis, whose district encompasses Martin County, told KFF Health News the rural health fund money “is essentially putting a band-aid on a much, much broader situation that needs dire help.” Davis has introduced legislation to increase Medicaid reimbursements for rural hospitals — the structural fix that would prevent hospital closures — but it has not moved forward.

    The closure of Martin General in August 2023 was abrupt. Employees were not notified. Patients being treated were wheeled out on stretchers and transported to other facilities. The company operating the county-owned hospital, Quorum Health, did not notify local elected leaders before filing for bankruptcy.

    Martin County also does not have paramedics on its ambulances — only emergency medical technicians (EMTs), who have a more limited scope of practice. The closest emergency rooms are 20 miles or more away, often overcrowded. One woman told KFF Health News she drove 2.5 hours from a small town near the Outer Banks so her 79-year-old aunt could get care at an ECU Health ER in Greenville — and was told to wait outside because of capacity issues.

    “It’s a real healthcare crisis that has already proven itself to have lost lives that perhaps didn’t have to be lost,” said ECU Health COO Brian Floyd. “They just want to not die because there’s nowhere to go when you have an emergency.”

    Frequently Asked Questions

    What is the $50 billion rural health fund?

    The Rural Health Transformation Program, included in the One Big Beautiful Bill Act, provides $10 billion per year for five years (FY 2026–2030) for rural health. CMS has broad discretion over distribution, and distribution decisions are not subject to administrative or judicial review.

    Why won’t the fund reopen Martin County’s hospital?

    Because the fund is distributed to existing health and social service organizations, and federal regulations limit how much can be spent on construction and renovation. Martin General Hospital closed in 2023 — it is not an existing operational facility that can receive funding. Martin County’s situation requires capital investment in a closed hospital that the fund’s design specifically does not accommodate.

    Does the $50 billion offset the Medicaid cuts in the same bill?

    Only partially. KFF estimates the fund could offset approximately 37% of the $137 billion in estimated cuts to federal Medicaid spending in rural areas over ten years. Critically, the fund runs through FY 2030, but nearly two-thirds of the Medicaid cuts occur after that — meaning the fund’s support ends before most of the cuts’ impact materializes.

    What happened to Martin County’s hospital?

    Martin General Hospital, the county’s only hospital, closed abruptly in August 2023 when the company operating it (Quorum Health) filed for bankruptcy without notifying local elected leaders or staff. Patients were wheeled out on stretchers. The county has approximately 22,000 residents with no hospital, no paramedics on ambulances, and emergency rooms 20+ miles away.

    What would it take to reopen Martin General?

    ECU Health has a letter of intent to reopen it as a rural emergency hospital (REH), but the plan requires the North Carolina General Assembly to appropriate $210 million to ECU Health and Martin County to fund building refurbishment. Those appropriations have not materialized. ECU Health’s CEO has separately warned the system expects to lose $1 billion over the next 10 years from Medicaid cuts under the One Big Beautiful Bill Act.

    Source link

  • Genicular Artery Embolization Delivered 12 Months of Knee Arthritis Pain Relief without Surgery in Nearly 200 Patients

    Genicular Artery Embolization Delivered 12 Months of Knee Arthritis Pain Relief without Surgery in Nearly 200 Patients

    For millions of people living with knee osteoarthritis, the current treatment ladder has a frustrating middle step that is largely empty. Conservative measures — physical therapy, NSAIDs, corticosteroid injections — provide relief that wanes over months. Full joint replacement surgery is effective but invasive, carries surgical risks, requires weeks of rehabilitation, and comes with a prosthetic lifespan of 15 to 20 years, making it poorly suited for younger or less medically robust patients who face decades of living with arthritis.

    Between those two rungs is a gap that has driven years of research into minimally invasive interventional options. A study published June 16, 2026, in Radiology — the flagship journal of the Radiological Society of North America — now provides the strongest evidence yet that one of those options delivers a full year of meaningful pain relief and functional improvement for appropriately selected patients.

    “For many patients with knee osteoarthritis, there is a real treatment gap today,” said lead author Florian Nima Fleckenstein, M.D., deputy head of Interventional Radiology Campus Mitte at Charité — Universitätsmedizin Berlin. “Conservative measures such as intra-articular injections no longer provide sufficient relief, but joint replacement is not an option for medical or personal reasons.”

    What Genicular Artery Embolization Is — and How It Works

    Genicular artery embolization (GAE) is a minimally invasive procedure performed by interventional radiologists using fluoroscopy (real-time X-ray imaging) and catheter-based techniques. The procedure targets a specific feature of the arthritic knee joint that conventional treatments have largely ignored: abnormal blood vessel formation.

    According to ScienceDaily’s coverage, in a healthy knee, the synovial tissue and supporting structures maintain a normal, controlled blood supply. In osteoarthritis, the chronic inflammation process triggers the growth of abnormal new blood vessels — called neovascularization — in and around the joint. These pathological vessels contribute to sustained inflammation and pain. Standard treatments target the inflammation downstream; GAE targets the vascular supply driving it.

    During GAE, an interventional radiologist threads a thin catheter through a puncture in the femoral artery, navigates it to the genicular arteries supplying the knee, and injects tiny microspheres that block blood flow to the abnormal vessels. By shutting down these pathological vessels, the procedure aims to reduce the vascular contribution to joint inflammation — producing pain relief and functional improvement without cutting, implanting, or removing anything.

    The version studied in the June 2026 Radiology paper uses rapidly resorbable, gelatin-based microspheres — a key distinction from earlier GAE studies that used permanent microspheres. The resorbable particles dissolve in the body over time, potentially reducing risks associated with permanent vascular occlusion in the lower extremity.

    GAE Radiology Study Key Data (June 16, 2026) Detail
    Published in Radiology (RSNA), June 16, 2026
    DOI 10.1148/radiol.253312
    Lead author Florian Nima Fleckenstein, M.D., Charité – Universitätsmedizin Berlin
    Total patients included 333
    Patients analyzed at 12-month follow-up 272
    Microsphere type Rapidly resorbable gelatin-based microspheres
    Follow-up period 12 months
    Key finding Significant, lasting pain relief + improved functional outcomes + improved quality of life at 12 months
    Safety Established; described as “real confidence” by Dr. Fleckenstein
    Procedure type Minimally invasive; image-guided catheter-based; outpatient
    Comparison No randomized placebo control — observational cohort design
    Global OA knee prevalence (WHO) 365 million adults
    U.S. OA prevalence ~32.5 million adults

    What the Study Found — and Why Scale Matters

    According to the Radiology abstract, 333 patients were included in the study, with 272 analyzed at the 12-month follow-up point. “This lets us speak about safety and efficacy with real confidence,” Dr. Fleckenstein told ScienceDaily. The study used validated outcome measures, including patient-reported pain scores and functional assessments, to document improvement.

    The clinical finding was clear: in patients with symptomatic knee osteoarthritis, GAE using rapidly resorbable microspheres provided long-lasting pain relief, improved functional outcomes, and enhanced quality of life across the 12-month observation period.

    According to Applied Radiology’s analysis, Dr. Fleckenstein framed the study’s significance specifically: “This study addresses osteoarthritis, which is a significant public health issue and the leading cause of chronic pain and disability worldwide. With millions of people affected by knee osteoarthritis, particularly in aging populations, finding effective, minimally invasive treatments is critical.”

    “GAE has the potential to reduce the need for more invasive surgeries, lower healthcare costs and significantly improve the quality of life for countless individuals suffering from knee osteoarthritis,” Dr. Fleckenstein added.

    An important technical caveat: this is a prospective observational cohort study, not a randomized controlled trial with a placebo or sham procedure comparison group. The absence of a randomized control arm means the study cannot fully exclude the placebo effect and selection bias as contributors to the observed outcomes. The evidence base for GAE is growing — including prior trials with permanent microspheres that also showed benefit — but the gold-standard randomized trial with a sham control remains an important next step in confirming GAE’s efficacy.

    Who Is an Appropriate Candidate for GAE?

    The procedure is designed for patients who have osteoarthritis-related knee pain that is no longer adequately controlled by conservative measures (physical therapy, NSAIDs, injections) but who are not candidates for or do not wish to pursue joint replacement surgery. This includes:

    • Patients who are too young or too active for joint replacement (where prosthetic lifespan becomes a concern)
    • Patients with medical comorbidities that increase surgical risk
    • Patients on blood thinners or immunosuppressants that complicate surgery
    • Patients who have declined joint replacement for personal reasons
    • Patients for whom prior injections have provided diminishing returns

    GAE is not appropriate for patients with advanced, end-stage osteoarthritis where the joint has lost virtually all cartilage, nor for patients with inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis), local knee infection, significant peripheral arterial disease, or irreversible coagulopathy. Patient selection is performed by the interventional radiologist in consultation with an orthopedic specialist or rheumatologist.

    The procedure is typically performed in an outpatient or same-day surgery setting under conscious sedation. Recovery is significantly less demanding than joint replacement — most patients resume normal activities within days rather than weeks.

    The Road to Widespread Availability

    In the United States, GAE is currently performed primarily at academic medical centers and major hospital systems with active interventional radiology programs. It is not yet widely available at community hospitals. Insurance coverage is variable; Medicare and many private insurers have not universally adopted coverage policies for GAE, though this is an active and rapidly evolving area given the growing evidence base.

    The June 2026 Radiology study’s scale — 333 patients, 272 analyzed at 12 months — represents the largest body of evidence assembled for GAE using rapidly resorbable microspheres, and it is likely to support additional insurance coverage petitions and professional society guidance updates in the coming months.

    Frequently Asked Questions

    What is genicular artery embolization (GAE)?

    GAE is a minimally invasive procedure where an interventional radiologist uses a thin catheter to navigate to the blood vessels supplying an arthritic knee joint and injects small particles that block abnormal (pathological) vessels. By reducing the vascular contribution to joint inflammation, the procedure aims to provide sustained pain relief without surgery.

    How long does the pain relief from GAE last?

    In the June 2026 Radiology study, significant pain relief and improved functional outcomes were sustained at 12-month follow-up in the 272 patients analyzed. Longer-term follow-up data is still being collected.

    Is this better than cortisone injections?

    Cortisone (corticosteroid) injections typically provide relief lasting weeks to a few months. GAE has demonstrated 12-month sustained benefit in this study and prior research, suggesting it offers more durable relief than repeat injections for appropriately selected patients. However, direct head-to-head randomized comparison with injections has not yet been published.

    What does the procedure involve?

    An interventional radiologist makes a small puncture in the femoral artery, threads a catheter to the genicular arteries of the knee, identifies abnormal blood vessels using imaging, and injects tiny resorbable microspheres that block them. The procedure is performed under fluoroscopy guidance, typically with conscious sedation, in an outpatient setting.

    Is GAE covered by insurance?

    Coverage in the U.S. varies by insurer and is still evolving. Medicare and private insurers are reviewing coverage policies as the evidence base grows. Patients should check with their insurer and the interventional radiology team about coverage and prior authorization requirements.

    Source link

  • FDA Approves Xocova (Ensitrelvir): The First Oral COVID Pill You Take After Exposure — Before You Get Sick

    FDA Approves Xocova (Ensitrelvir): The First Oral COVID Pill You Take After Exposure — Before You Get Sick

    COVID-19 is still killing tens of thousands of Americans every year — and for the first time, there is now an FDA-approved oral medication that household contacts of infected individuals can take before symptoms develop to significantly reduce their risk of getting sick.

    On June 1, 2026, the U.S. Food and Drug Administration approved Xocova® (ensitrelvir), an oral antiviral developed by Japanese pharmaceutical company Shionogi, for post-exposure prophylaxis (PEP) of COVID-19 in adults and adolescents 12 years of age and older. It is the first and only oral option approved for preventing COVID-19 after exposure to an infected individual — a distinct and previously unaddressed clinical need.

    What Xocova Is — and How It Differs From Paxlovid

    The distinction between Xocova and Paxlovid (nirmatrelvir/ritonavir) is essential to understand, because they serve different purposes at different points in the COVID-19 timeline.

    Paxlovid is taken after a positive COVID test and symptom onset, to reduce the severity of illness in high-risk individuals who are already sick. It is a treatment for active disease.

    Xocova is taken after exposure to an infected individual, before the person becomes infected or symptomatic — a pre-symptomatic intervention window that previously had no oral pharmacological option in the United States. It is a prophylactic medication, not a treatment for existing infection.

    Mechanistically, both drugs target the same SARS-CoV-2 main protease (3CL protease) — a key enzyme the virus needs to replicate. By blocking this enzyme, Xocova prevents the virus from reproducing efficiently in newly exposed individuals, reducing the probability that a household exposure leads to established infection.

    According to the SCORPIO-PEP trial data published in the New England Journal of Medicine: in the primary endpoint analysis of 2,041 SARS-CoV-2-negative participants, only 2.9% of those in the ensitrelvir group developed symptomatic COVID-19 by day 10, compared with 9.0% in the placebo group — a 67% reduction in risk.

    Xocova (Ensitrelvir) Key Data Detail
    FDA approval date June 1, 2026
    Developer Shionogi (Japan)
    Indication Post-exposure prophylaxis (PEP) of COVID-19
    Age indication Adults and adolescents 12 years and older
    Phase 3 trial SCORPIO-PEP (NCT05897541)
    Primary endpoint result 67% lower risk of symptomatic COVID-19 (2.9% vs. 9.0%)
    Secondary analysis (all participants) 57% risk reduction
    Dosing regimen 375mg on Day 1 (3 tablets); then 125mg on Days 2–5 (1 tablet each)
    Duration 5 days
    Most common side effects Headache, diarrhea, cough (15.1% vs. 15.5% placebo)
    Prior approved COVID post-exposure option None (bamlanivimab withdrawn due to Omicron resistance)
    U.S. COVID cases Oct 2025 – May 2026 3.8–12.4 million (CDC estimate)
    U.S. COVID deaths Oct 2025 – May 2026 13,000–42,000 (CDC estimate)

    How the Trial Worked — and What the Results Mean

    The SCORPIO-PEP trial enrolled 2,387 individuals aged 12 and older who had tested negative for SARS-CoV-2 at enrollment and were living in a household with a confirmed COVID-19 case. Participants were randomized 1:1 to receive ensitrelvir or matching placebo for five days.

    According to AJMC, ensitrelvir was well tolerated — adverse event rates were nearly identical between the ensitrelvir group (15.1%) and placebo group (15.5%), with the most common events being headache, diarrhea, and cough. No serious safety signals were identified.

    A notable feature of the trial population: more than 99% of household contacts already had SARS-CoV-2 antibodies at baseline — meaning nearly the entire study population had pre-existing immunity from prior infection, vaccination, or both. TechTimes noted that the drug performed equally well in this highly immune population, confirming that Xocova’s benefit does not depend on immunological naivety. This is clinically significant: it means the medication is likely to work in 2026’s real-world population, nearly all of whom have some prior COVID immunity.

    Who Should Take Xocova — and When

    The critical timing parameter for Xocova is not yet formally defined by the FDA label as a specific hour cutoff, but the clinical logic — and the trial design — centers on initiating treatment as soon as possible after a confirmed household exposure, ideally within 24 to 72 hours.

    The populations with the most to gain include:

    • Adults 60 and older, who remain at highest risk of severe COVID outcomes
    • Immunocompromised individuals (transplant recipients, patients on chemotherapy, people with HIV, those on long-term immunosuppressive therapy)
    • Adults with significant comorbidities — heart disease, diabetes, chronic kidney disease, chronic lung disease, obesity
    • Residents and staff of long-term care facilities, where up to 47% of household-level contacts develop COVID following exposure to an infected person, according to Shionogi’s prescribing data
    • Adolescents 12 and older in high-risk households

    Anyone in one of these groups who has a confirmed household contact with COVID-19 should contact their healthcare provider immediately to discuss Xocova eligibility. The drug closes a therapeutic gap that has existed since bamlanivimab/etesevimab — the only prior authorized COVID post-exposure option — was withdrawn after proving ineffective against Omicron variants.

    “The approval for COVID-19 PEP was based on data from the SCORPIO-PEP trial, which demonstrated favorable safety and efficacy in uninfected pediatric and adult patients who had been exposed to an infected individual, reducing the risk of symptomatic COVID-19 by 67%,” AJMC reported.

    COVID-19 in 2026 — Why This Still Matters

    The approval arrives at a moment when COVID-19 has become background noise for many Americans but remains a significant cause of illness, hospitalization, and death. The CDC estimates that between October 1, 2025, and May 23, 2026, there were 3.8 to 12.4 million new COVID cases in the United States, resulting in 800,000 to 2.3 million outpatient visits, 120,000 to 240,000 hospitalizations, and 13,000 to 42,000 deaths. Long COVID — which produces lasting neurological, cardiovascular, and respiratory complications — adds a further layer of risk that prevention reduces. Preventing even a percentage of those infections among the highest-risk population represents a meaningful public health gain.

    Frequently Asked Questions

    What is Xocova (ensitrelvir) and what was it approved for?

    Xocova (ensitrelvir) was FDA-approved June 1, 2026, by Shionogi, as the first and only oral medication for post-exposure prophylaxis (PEP) of COVID-19. It is approved for adults and adolescents 12 and older who have had contact with a confirmed COVID-19 case.

    How is Xocova different from Paxlovid?

    Paxlovid is taken after a positive COVID test and symptom onset to reduce disease severity. Xocova is taken after exposure but before infection or symptom onset, to prevent the exposed person from developing COVID at all. They target the same viral enzyme but are used at different clinical moments.

    How effective is Xocova?

    In the Phase 3 SCORPIO-PEP trial, Xocova reduced the risk of symptomatic COVID-19 by 67% compared to placebo in household contacts who were initially SARS-CoV-2-negative, with a secondary analysis showing 57% risk reduction across all participants.

    How do you take Xocova?

    Xocova is a 5-day oral regimen: 3 tablets taken as a single dose on Day 1, then 1 tablet per day on Days 2 through 5. It should be started as soon as possible after a confirmed household exposure. Contact your healthcare provider immediately if you have been exposed.

    Who qualifies for Xocova?

    The FDA approval covers adults and adolescents 12 and older following contact with a confirmed COVID-19 case. People most likely to benefit include adults 60 and older, the immunocompromised, those with significant comorbidities, and long-term care residents and staff. A healthcare provider should assess individual eligibility.

    Source link

  • GLP-1 Drugs Like Ozempic Are Showing a 47 Percent Reduction in Breast Cancer Risk in a Major New Study — and Weight Loss May Not Explain It

    GLP-1 Drugs Like Ozempic Are Showing a 47 Percent Reduction in Breast Cancer Risk in a Major New Study — and Weight Loss May Not Explain It

    The list of conditions that GLP-1 receptor agonists appear to protect against keeps getting longer. These drugs — which include semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and the newly approved orforglipron (Foundayo) — were originally developed for type 2 diabetes before emerging as transformative obesity medications. Then cardiovascular outcome trials showed they reduce heart attacks and strokes. Then the sleep apnea approval added obstructive sleep apnea to the indication list. Then studies suggested reductions in kidney disease progression, non-alcoholic fatty liver disease, and alcohol dependence.

    And now, a major study presented at the American Society of Clinical Oncology Annual Meeting in Chicago in early June 2026 and reported widely on June 10, 2026 has added breast cancer to the rapidly expanding list of conditions that GLP-1 drugs appear to protect against — with an effect magnitude that has stunned the oncology community.

    The study, which analyzed real-world data from a large cohort of women with type 2 diabetes or obesity who were treated with GLP-1 receptor agonists, found that GLP-1 drug use was associated with a 30 to 47 percent lower risk of developing breast cancer compared to women who did not use these medications. The lower end of that range (30 percent) emerged from analyses adjusted for body mass index and weight change — meaning even when researchers accounted for the weight loss that GLP-1 drugs produce, a significant protective signal remained. This finding strongly suggests that GLP-1 drugs may be protecting against breast cancer through mechanisms that go beyond simply reducing body fat — mechanisms that may include direct anti-tumor effects, reduced insulin resistance and associated growth factor signaling, or anti-inflammatory pathways.

    Why This Finding Is Biologically Plausible

    The biological connection between metabolic dysfunction, obesity, insulin resistance, and breast cancer risk is well established. Adipose tissue (fat) produces estrogen through a process called aromatization, making obesity a direct driver of estrogen-dependent breast cancers. Hyperinsulinemia — the elevated insulin levels that accompany insulin resistance in type 2 diabetes and obesity — activates the insulin-like growth factor (IGF-1) pathway, which promotes cancer cell proliferation and survival. Chronic inflammation from adipose tissue dysfunction activates oncogenic pathways that promote tumor growth.

    GLP-1 receptor agonists address multiple of these pathways simultaneously. They reduce body fat (reducing aromatization and adipose inflammation), improve insulin sensitivity (reducing hyperinsulinemia and IGF-1 signaling), and have direct anti-inflammatory effects. Preclinical studies have also documented direct GLP-1 receptor agonist activity on cancer cell lines, suggesting GLP-1 receptors may be expressed in breast cancer tissue and may mediate direct anti-proliferative effects when activated.

    The study’s finding that the protective signal persists even after adjustment for weight and BMI is the most provocative result, because it suggests the drug’s biological effects — beyond simple caloric restriction and fat mass reduction — are contributing to cancer protection.

    What This Means for the 15 Million Americans on GLP-1 Drugs

    Approximately 15 million Americans are currently prescribed GLP-1 receptor agonists. The vast majority are taking them for type 2 diabetes or weight management. If the breast cancer protective signal seen in this study is confirmed in larger prospective trials and in controlled analyses, it would represent an additional major health benefit of these medications — one that could influence prescribing decisions, insurance coverage arguments, and cancer prevention discussions.

    The researchers caution that this is observational data from a real-world cohort, not a randomized controlled trial. Confounding variables — the possibility that GLP-1 drug users differ from non-users in ways that independently affect breast cancer risk — must be accounted for before these findings can be considered definitive. Prospective studies and potential randomized trials with cancer outcomes as endpoints are now being planned. The Phase 3 ORCA trial of semaglutide in high-risk cancer prevention populations is one ongoing effort that will provide higher-quality evidence.

    For women currently taking GLP-1 drugs for any indication, this study is not a recommendation to take them as cancer prevention without diabetes or obesity indication — rather, it is an important signal that the health benefits of these medications may be broader than previously understood.

    Frequently Asked Questions

    Q: What did the new GLP-1 and breast cancer study find?

    A: A real-world cohort study presented at ASCO 2026 found that women with type 2 diabetes or obesity who used GLP-1 receptor agonists had a 30–47% lower breast cancer risk compared to non-users. The effect persisted after adjustment for weight loss.

    Q: Does this mean women should take GLP-1 drugs specifically to prevent breast cancer?

    A: No. This is observational data, not a randomized trial. The finding is a promising signal that warrants further research, not a clinical recommendation for GLP-1 drugs as cancer prevention outside of established indications.

    Q: Why might GLP-1 drugs protect against breast cancer beyond weight loss?

    A: By reducing hyperinsulinemia, improving insulin sensitivity (lowering IGF-1 signaling), reducing adipose-tissue inflammation, and potentially through direct GLP-1 receptor activity on breast tissue — all mechanisms independent of weight loss.

    Q: Which GLP-1 drugs were included in the study?

    A: The study analyzed GLP-1 receptor agonist use broadly, including semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) among the most commonly used agents. Results were not limited to a specific drug within the class.

    Q: How does this new finding fit with the other cancer data on GLP-1 drugs?

    A: A 2024 Nature Medicine study documented lower incidence of multiple obesity-associated cancers in GLP-1 users. The 2026 ASCO breast cancer study adds specifically to that growing body of evidence suggesting GLP-1 drugs may have broad anti-cancer properties.

    Source link

  • Chikungunya Outbreaks Are Now Active in Three Different Countries and Territories Simultaneously — and Summer Travelers Are at Risk from the Caribbean to the Indian Ocean

    Chikungunya Outbreaks Are Now Active in Three Different Countries and Territories Simultaneously — and Summer Travelers Are at Risk from the Caribbean to the Indian Ocean

    Summer 2026 has produced an unusual public health picture on the CDC Travel Health Notices page: three simultaneous active travel notices for chikungunya — the mosquito-borne virus known for causing weeks of debilitating joint pain — across three different geographic regions. Suriname, a country on the northeastern coast of South America, has had an active chikungunya outbreak since February 2026. Mayotte, a French territory in the Indian Ocean off the coast of Mozambique, has been under a CDC chikungunya notice since March 10, 2026. And French Guiana, the French overseas territory on the northern coast of South America adjacent to Brazil, received a new CDC travel notice for chikungunya on June 4, 2026 — just 10 days ago.

    Three simultaneous active outbreaks across two continents and the Indian Ocean, all in destinations that receive American travelers during peak summer season, all involving the same virus, and all preventable by a vaccine that most American travelers have never heard of.

    Chikungunya is caused by the chikungunya alphavirus, transmitted primarily by Aedes aegypti and Aedes albopictus mosquitoes — the same species responsible for dengue fever and Zika virus transmission. It cannot spread person to person. It requires a mosquito bite for transmission, which means travelers who effectively prevent mosquito bites can protect themselves. But unlike dengue — for which no reliably effective, widely available vaccine existed in the U.S. until recently — chikungunya now has an FDA-approved single-dose vaccine that provides broad, durable protection.

    The Pattern of These Three Simultaneous Outbreaks

    The geographic distribution of the three current CDC chikungunya notices reflects distinct but parallel epidemiological situations. In Suriname, chikungunya has been circulating since at least February 2026, consistent with the country’s tropical climate that supports year-round Aedes mosquito activity. Suriname borders Guyana to the west, Brazil to the south, and French Guiana to the east — meaning outbreak activity in Suriname creates risk for cross-border spread to adjacent territories, and the French Guiana notice issued June 4 is likely connected to regional transmission dynamics that began in Suriname and Brazil.

    Mayotte’s chikungunya outbreak is separate in origin — the island’s subtropical Indian Ocean climate creates independent conditions for Aedes activity, and chikungunya has a well-documented history of large outbreak cycles in Indian Ocean territories, including the catastrophic 2005–2006 outbreak in La Réunion that infected nearly one-third of the island’s population.

    What these three outbreaks share is the presence of Aedes aegypti or Aedes albopictus at epidemic transmission levels, a population of susceptible individuals without prior immunity, and the current arrival of the summer travel season, which increases the probability of importation to the United States via returning travelers.

    What Chikungunya Does to the Human Body

    The word chikungunya comes from the Makonde language of Tanzania, meaning “that which bends up” — a reference to the stooped posture that patients adopt in response to severe joint pain. The description is medically accurate and experientially unforgettable. After an incubation period of 2 to 12 days following a mosquito bite, patients develop sudden high fever — often above 103°F — accompanied by polyarthralgia, the simultaneous severe painful inflammation of multiple joints. The hands, wrists, ankles, and feet are most commonly affected, and the pain is frequently described by patients as worse than anything they have experienced. Many cannot walk, dress, or grip a cup.

    The acute phase typically lasts 7 to 10 days. Most patients recover. But approximately 25 to 50 percent of people infected with chikungunya develop chronic post-chikungunya arthritis — persistent joint pain that continues for months to years after the initial infection has resolved. This is the longest-lasting and most debilitating consequence of chikungunya, and it disproportionately affects older adults and those with pre-existing joint disease.

    The Vaccine That Travelers Are Not Getting

    The FDA approved Ixchiq (chikungunya vaccine) in November 2023 for adults 18 and older at increased risk of chikungunya exposure. Ixchiq is a live-attenuated, single-dose vaccine that requires no booster and has demonstrated strong immunogenicity and an acceptable safety profile in clinical trials. It is available through travel medicine clinics and many primary care providers.

    Despite its approval, Ixchiq remains significantly underutilized among American travelers to chikungunya-endemic and outbreak-affected regions. Awareness of the vaccine’s existence is low among both patients and some general practitioners who do not specialize in travel medicine. Travelers heading to Suriname, French Guiana, Mayotte, or any of the many Caribbean and South American destinations currently experiencing elevated chikungunya activity should specifically ask about Ixchiq at their travel medicine consultation.

    The vaccine requires at least 28 days to induce full protection, so travelers should plan accordingly — those departing within 28 days should be advised to rely on intensive mosquito bite prevention while the vaccine becomes effective, or may not benefit from vaccination for their current trip. As with all mosquito-borne disease prevention, repellent use, protective clothing, air conditioning, and bed nets remain essential complements to vaccination.

    Frequently Asked Questions

    Q: Where are the current chikungunya outbreaks with CDC travel notices?

    A: As of June 2026, active CDC chikungunya travel notices cover Suriname (February 2026), Mayotte, a French Indian Ocean territory (March 10, 2026), and French Guiana (June 4, 2026).

    Q: What are the symptoms of chikungunya?

    A: Sudden high fever and severe polyarthralgia — simultaneous joint pain in multiple joints, especially the hands, wrists, ankles, and feet — beginning 2 to 12 days after a mosquito bite. The pain is frequently described as the worst the patient has ever experienced. Most cases resolve within 7 to 10 days, but 25–50% develop chronic joint pain lasting months to years.

    Q: Is there a vaccine for chikungunya?

    A: Yes. Ixchiq is an FDA-approved single-dose live-attenuated vaccine for adults 18 and older. It was approved November 2023 and is available at travel medicine clinics. It requires approximately 28 days to become fully effective.

    Q: Who should get vaccinated against chikungunya before travel?

    A: Adults 18 and older traveling to areas with active chikungunya transmission who will have outdoor exposure to mosquitoes. This currently includes travelers to Suriname, French Guiana, Mayotte, and other active outbreak areas.

    Q: How is chikungunya different from dengue fever?

    A: Both are transmitted by Aedes mosquitoes and cause fever. Chikungunya is distinguished by the severe arthralgia (joint pain) that dominates its clinical picture and can persist for months to years. Dengue more commonly causes a characteristic rash, severe headache, and potentially hemorrhagic complications.

    Source link

  • First-in-Class Drug Targeting Treatment-Resistant High Blood Pressure Wins FDA Approval — and Works Like No Existing Drug

    First-in-Class Drug Targeting Treatment-Resistant High Blood Pressure Wins FDA Approval — and Works Like No Existing Drug

    High blood pressure — hypertension — is the single most treatable risk factor for cardiovascular disease and stroke, the two leading causes of death in the United States. There are already more than a dozen classes of antihypertensive medications. For most patients, combining two or three of these drugs in appropriate doses achieves adequate blood pressure control and dramatically reduces the risk of heart attack, stroke, kidney failure, and premature death.

    But for a significant subset — estimated at 10 to 15 percent of all hypertensive patients — blood pressure remains uncontrolled despite taking two, three, or even four medications at maximum tolerated doses. This is called resistant hypertension, and it represents one of the most clinically frustrating situations in internal medicine: a patient taking a handful of pills every day, experiencing their side effects, and still not achieving the blood pressure target that determines their future risk of cardiovascular catastrophe.

    For these patients, the FDA’s May 18, 2026 approval of baxdrostat (Baxfendy) — developed by AstraZeneca — represents the arrival of a fundamentally new therapeutic option built on a mechanism of action that no previously approved drug has ever targeted in this indication.

    “We have been waiting for an innovative medication like BAXFENDY for hypertension for many years,” said Bryan Williams, MD, Chair of Medicine at University College London and a primary investigator for the pivotal BaxHTN trial. “Its novel way of lowering blood pressure has the potential to transform clinical practice by targeting a root cause of persistently uncontrolled hypertension.”

    The Aldosterone Problem and Why Existing Drugs Miss It

    Aldosterone is a steroid hormone produced by the adrenal glands that regulates sodium and water retention in the kidneys. When aldosterone levels are excessive — whether due to a benign adrenal tumor (primary aldosteronism), stress-related overproduction, or other dysregulation — the kidneys retain too much sodium and water, blood volume rises, and blood pressure increases in a way that does not respond well to most standard antihypertensive mechanisms.

    The renin-angiotensin-aldosterone system (RAAS) is already a major target of existing hypertension drugs: ACE inhibitors, ARBs, and direct renin inhibitors all interfere with the pathway that leads to aldosterone production. But these drugs do not directly target aldosterone synthase — the specific enzyme, encoded by the CYP11B2 gene, that is the final step in aldosterone manufacturing in the adrenal gland. Blocking earlier steps in the RAAS leaves aldosterone synthase activity largely intact, allowing it to produce aldosterone through compensatory mechanisms.

    Baxdrostat is a selective aldosterone synthase inhibitor — a small-molecule oral drug that directly and selectively inhibits CYP11B2, preventing aldosterone from being synthesized in the first place. This selectivity is critical: the enzyme CYP11B1, which produces cortisol and sits in a closely adjacent biochemical pathway, is not significantly affected by baxdrostat at therapeutic doses. This means baxdrostat lowers aldosterone — and therefore blood pressure — without disrupting the cortisol axis that regulates the stress response, immune function, and metabolism. AstraZeneca confirmed in clinical trials that baxdrostat lowered aldosterone levels without affecting cortisol levels.

    What the BaxHTN Phase 3 Trial Found

    The BaxHTN trial enrolled 796 patients with uncontrolled or resistant hypertension — all already on at least two antihypertensive agents, including a diuretic — and randomized them 1:1:1 to receive baxdrostat 2 mg once daily, baxdrostat 1 mg once daily, or placebo in addition to their background therapy, for 12 weeks.

    At week 12:

    • Patients on baxdrostat 2 mg had a 15.7 mmHg reduction in seated systolic blood pressure from baseline — a 9.8 mmHg placebo-adjusted reduction.
    • Patients on baxdrostat 1 mg had a 14.5 mmHg reduction — an 8.7 mmHg placebo-adjusted reduction.
    • The placebo group had a 5.8 mmHg reduction from baseline.

    Both doses met the primary endpoint of statistically significant systolic blood pressure reduction. The findings were consistent in patients with both uncontrolled hypertension (not at goal despite two or more drugs) and truly resistant hypertension (not at goal despite three or more drugs, including a diuretic). Results were also supported by a separate Phase 3 Lancet-published Bax24 trial using ambulatory blood pressure monitoring, confirming the effect on 24-hour blood pressure rather than only the clinic reading.

    A 9.8 mmHg reduction in systolic blood pressure is not a cosmetic number. Systematic reviews of blood pressure interventions consistently show that each 5 mmHg reduction in systolic blood pressure reduces the risk of major cardiovascular events by approximately 10 percent. For patients whose blood pressure has been inadequately controlled despite multiple medications — meaning they have been living with elevated cardiovascular risk despite treatment — a nearly 10 mmHg additional reduction is clinically meaningful and potentially life-extending.

    Who Will Benefit and What Comes Next

    Baxfendy is approved as an add-on oral treatment for adults with hypertension not adequately controlled on other medications. It is taken once daily in 1 mg or 2 mg doses. The key safety considerations identified in trials are hyperkalemia (elevated blood potassium), which requires periodic monitoring, and hyponatremia (low sodium) in some patients. Neither was dose-limiting in the vast majority of trial participants.

    The drug received Fast Track and Breakthrough Therapy designations from the FDA during development, signaling the agency’s recognition of the unmet need it addresses. AstraZeneca is also studying baxdrostat in additional conditions where aldosterone excess plays a mechanistic role, including chronic kidney disease and heart failure — conditions that frequently co-occur with resistant hypertension.

    Frequently Asked Questions

    Q: What is baxdrostat (Baxfendy) and who is it for?

    A: Baxdrostat is the first-ever oral aldosterone synthase inhibitor, FDA-approved May 18, 2026 as an add-on treatment for adults with hypertension not adequately controlled on other antihypertensive medications.

    Q: How does baxdrostat work differently from other blood pressure drugs?

    A: It directly and selectively inhibits aldosterone synthase (the CYP11B2 enzyme), preventing aldosterone production at its source. No previously approved drug has targeted this specific enzyme. Existing RAAS drugs act earlier in the pathway and leave aldosterone synthase partially active.

    Q: How much does baxdrostat lower blood pressure?

    A: In the BaxHTN Phase 3 trial, baxdrostat 2 mg added to background therapy produced a 9.8 mmHg placebo-adjusted reduction in systolic blood pressure at 12 weeks. The 1 mg dose achieved an 8.7 mmHg reduction.

    Q: Does baxdrostat affect cortisol levels?

    A: No. Baxdrostat selectively inhibits CYP11B2 (aldosterone synthase) without significantly affecting CYP11B1 (cortisol synthesis). Clinical trials confirmed aldosterone reductions without changes in cortisol.

    Q: What are the main side effects of baxdrostat?

    A: Hyperkalemia (elevated potassium) and hyponatremia (low sodium) are the primary safety considerations, both requiring periodic monitoring. Neither was dose-limiting in most trial participants.

    Source link

  • CRISPR Gene Editing Achieves a Functional Cure for Sickle Cell Disease in 96 Percent of Patients — RUBY Trial Results in the New England Journal of Medicine Are Historic

    CRISPR Gene Editing Achieves a Functional Cure for Sickle Cell Disease in 96 Percent of Patients — RUBY Trial Results in the New England Journal of Medicine Are Historic

    The phrase “functional cure” is used carefully in medicine — it describes an outcome in which a disease’s effects are so effectively suppressed that the patient lives as though they do not have it, even if the underlying genetic cause remains. For sickle cell disease, a condition that has caused lifelong suffering, organ damage, and premature death for 100,000 Americans and millions globally, achieving a functional cure through gene editing is one of the most profound accomplishments medicine has produced in years.

    The RUBY Trial, published in the New England Journal of Medicine on April 1, 2026, has delivered exactly that result. Of 28 patients with severe sickle cell disease who were treated with renizgamglogene autogedtemcel (reni-cel) — a CRISPR-Cas12a gene editing therapy that modifies patients’ own blood-forming stem cells — 27 (96 percent) had no painful sickle cell crises for up to two years following treatment. Their average hemoglobin levels rose to near-normal levels, effectively restoring the oxygen-carrying capacity that sickle-shaped red blood cells cannot provide.

    “We have seen that a benefit of this CRISPR/Cas12a gene-editing technology is that there is no rejection, so it’s different from traditional bone marrow transplants, which is standard treatment for sickle cell patients currently,” said Dr. Rabi Hanna, lead author and chair of the Pediatric Hematology-Oncology and Blood and Bone Marrow Transplant Division at Cleveland Clinic Children’s, who led the multicenter trial sponsored by Editas Medicine. “Our aim has been to achieve a functional cure to help prevent any future damage caused by sickle cell disease, and these latest results are compelling.”

    How Reni-Cel Works — and Why Cas12a Matters

    Reni-cel uses CRISPR-Cas12a gene editing to target the promoter regions of the HBG1 and HBG2 genes — the switches that normally suppress fetal hemoglobin production after birth. By editing these promoters, reni-cel reactivates the production of fetal hemoglobin (HbF) in adult red blood cells. Since fetal hemoglobin does not sickle, its presence in sufficient quantities effectively dilutes or displaces the dysfunctional sickle hemoglobin, preventing the cell deformation that causes sickle cell crises, organ damage, and shortened life expectancy.

    This approach is distinct from Casgevy (exa-cel) — the first approved CRISPR therapy for sickle cell disease, using CRISPR-Cas9 to target BCL11A, a different suppressor of fetal hemoglobin. Reni-cel uses CRISPR-Cas12a, which has a different molecular structure and cutting mechanism from Cas9, and targets HBG1/HBG2 directly rather than through BCL11A. The two approaches achieve similar biological endpoints — fetal hemoglobin reactivation — through different molecular pathways, meaning they may offer complementary options for patients in whom one approach is less effective.

    The 28 patients — four of whom were treated at Cleveland Clinic Children’s — underwent a procedure in which their stem cells were first collected and taken to a laboratory where the gene editing was performed. They then received chemotherapy to clear their bone marrow, making room for the repaired cells, which were infused back into their bodies. Within weeks of engraftment, fetal hemoglobin levels began rising. Most patients’ hemoglobin reached near-normal values within the first several months — and the patients themselves experienced what the data describe: two years without a painful crisis.

    Access and What Comes Next

    Reni-cel is not yet FDA-approved. The RUBY Trial data represent Phase 1/2 trial results — sufficient to demonstrate safety and early efficacy, but additional confirmatory data and FDA submission will be needed before approval. Editas Medicine, the trial sponsor, is expected to proceed with regulatory submission based on these results. The cost challenge that affects Casgevy — approximately $2.2 million per patient — will also apply to reni-cel, making equitable access a critical policy question for the approximately 100,000 Americans with sickle cell disease, most of whom are Black or Latino, a demographic that has faced persistent underinvestment in sickle cell research and treatment infrastructure for decades.

    Frequently Asked Questions

    Q: What were the RUBY Trial results?

    A: 27 of 28 patients (96%) with severe sickle cell disease had zero painful sickle cell crises for up to two years after treatment with reni-cel. Their average hemoglobin levels rose to near-normal.

    Q: How is reni-cel different from Casgevy?

    A: Reni-cel uses CRISPR-Cas12a to edit the HBG1 and HBG2 fetal hemoglobin promoters directly. Casgevy uses CRISPR-Cas9 to target BCL11A. Both reactivate fetal hemoglobin but through different molecular pathways.

    Q: Is reni-cel FDA-approved?

    A: No. The RUBY Trial is Phase 1/2. FDA submission is expected based on these results. Casgevy is already FDA-approved and represents the current available option.

    Q: How many Americans have sickle cell disease?

    A: Approximately 100,000 Americans, disproportionately African American and Latino.

    Q: Why is gene editing potentially better than bone marrow transplant for sickle cell?

    A: Because patients use their own edited cells, eliminating the need for a matched donor and removing the risk of graft-versus-host disease — the immune attack that is the major complication of donor-based bone marrow transplants.

    Source link

  • HHS Asks the Public What Works for Addiction Treatment in New Federal Request for Comment — Here Is Why It Matters

    HHS Asks the Public What Works for Addiction Treatment in New Federal Request for Comment — Here Is Why It Matters

    The U.S. Department of Health and Human Services published a Request for Information in the Federal Register on June 10, 2026, inviting public comment on which research, programs, and policies have been most successful in treating addiction, improving mental health outcomes, and supporting long-term recovery. The comment period runs through July 5, 2026, and is framed as part of HHS Secretary Robert F. Kennedy Jr.’s broader initiative, the administration has called the “Great American Recovery.”

    The RFI arrives at a sobering moment for American public health. Opioid overdose deaths have remained above 70,000 annually since 2017 and exceeded 80,000 in 2024, making drug overdose one of the leading causes of death among Americans under age 55. Fentanyl and other synthetic opioids now account for the vast majority of these deaths. The toll extends far beyond mortality statistics — addiction devastates families, communities, workforce participation, and the children of people with substance use disorders.

    The notice explicitly invites input from patients, people with lived experience of addiction and recovery, healthcare providers, community organizations, and researchers. The framing reflects a genuine uncertainty about the best path forward at the federal level — and, depending on how the administration responds to the comments received, could foreshadow significant shifts in federal drug and mental health policy.

    What the Science Says About Addiction Treatment

    The research base for addiction treatment has expanded substantially over the past two decades, and several evidence-based approaches have demonstrated consistent results. Medication-assisted treatment (MAT) for opioid use disorder — using buprenorphine (Suboxone), methadone, or naltrexone (Vivitrol) — remains the most extensively studied and most effective approach for reducing overdose deaths and helping patients maintain recovery. A landmark 2023 study in the New England Journal of Medicine found that patients receiving buprenorphine had significantly lower rates of overdose death than those who did not.

    Despite this evidence, access to MAT remains severely limited. Fewer than 20 percent of people with opioid use disorder receive it, partly due to stigma, provider reluctance to prescribe, geographic disparities, and insurance barriers. Advocacy groups and harm reduction organizations have consistently pushed for more accessible prescribing, expanded availability in emergency departments, and removal of administrative barriers to buprenorphine.

    Residential treatment, peer support specialists, contingency management (which uses positive reinforcement to promote drug-free behavior and is especially effective for stimulant use disorders), and community-based case management have all shown benefit in specific contexts. Mental health co-treatment is also increasingly recognized as essential, given that the majority of people with substance use disorders have co-occurring anxiety, depression, trauma, or other psychiatric conditions.

    Harm reduction strategies — needle exchange programs, naloxone distribution, fentanyl test strips, supervised consumption sites — have a strong evidence base for reducing overdose deaths and HIV transmission, though they remain politically controversial and are not universally available.

    What Advocates Want the Administration to Hear

    Public health advocates are watching this comment process closely. Many are hoping the RFI signals a genuine commitment to expanding evidence-based treatment access rather than a pivot toward approaches that lack a strong scientific foundation. Questions about how the Kennedy-led HHS will address the scientific consensus on MAT, harm reduction, and the role of abstinence-only models will shape the federal response for years.

    The comment process is open to all members of the public at federalregister.gov. Comments submitted by the July 5, 2026 deadline will inform HHS policy development.

    Frequently Asked Questions

    Q: What is the HHS asking for in this public comment request?

    A: HHS is seeking input on which addiction treatment programs, policies, and research approaches have been most successful — to guide future federal policy and funding priorities.

    Q: What are the most effective treatments for opioid use disorder?

    A: Medication-assisted treatment (MAT) using buprenorphine, methadone, or naltrexone has the strongest evidence base. Combined with counseling and support services, MAT significantly reduces overdose deaths.

    Q: How many Americans die of opioid overdoses each year?

    A: Opioid overdose deaths exceeded 80,000 in 2024. Fentanyl and synthetic opioids now account for the vast majority of these deaths.

    Q: How can I submit comments to the HHS RFI?

    A: Comments can be submitted at federalregister.gov by the July 5, 2026 deadline.

    Q: What is harm reduction and why is it controversial?

    A: Harm reduction includes strategies like naloxone distribution, needle exchanges, and fentanyl test strips that reduce the risks of drug use without requiring abstinence. Evidence strongly supports their effectiveness, but they remain politically controversial in some settings.

    Source link